BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rugo HS, Haltner A, Zhan L, Tran A, Bananis E, Hooper B, Mitra D, Cameron C. Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer. J Comp Eff Res 2021;10:457-67. [PMID: 33626934 DOI: 10.2217/cer-2020-0272] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Dormer L. Celebrating 10 years of the Journal of Comparative Effectiveness Research. J Comp Eff Res 2022;11:1-5. [PMID: 34872331 DOI: 10.2217/cer-2021-0249] [Reference Citation Analysis]
2 Law E, Gavanji R, Walsh S, Haltner A, McTavish R, Cameron C. Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. J Comp Eff Res 2021. [PMID: 34751591 DOI: 10.2217/cer-2021-0221] [Reference Citation Analysis]